England has made real headway against tuberculosis over the past fifteen years — but the world as a whole has not caught up, and recent figures show the disease remains far more widespread than treatment systems can handle.

TB ranks as the deadliest single infectious disease globally after COVID-19, infecting more than ten million people annually, according to the UK Health Security Agency. Yet in 2022, only 7.5 million of an estimated 10.6 million TB cases were actually diagnosed, Reuters reported citing WHO data. That leaves more than three million people with active TB completely outside the healthcare system. This diagnostic gap is not recent — WHO documented roughly the same three-million shortfall back in 2012 — but the fact that it has persisted through a decade of global TB strategies shows how little structural progress has been made.

England's experience tells a different story. Public Health England, NHS England, and local partners achieved a 38% drop in new TB cases between 2011 and 2017, from 8,280 down to 5,102 according to UKHSA. By 2021, notifications fell further to 4,425 — a rate of 7.8 per 100,000 population per UKHSA. Mortality also shifted: the proportion of TB patients dying each year in England dropped from 7.1% in 2002 to 5.5% in 2014.

These gains came from targeted public health work. Contact tracing, latent TB treatment (essentially preventive therapy for people carrying the dormant infection), and focused screening of communities with higher TB rates all played roles. Yet the system had visible weaknesses even as overall cases fell. Research from 2011 showed that TB screening at UK ports of entry was missing most cases among new arrivals — a structural problem that required years of policy refinement to partially fix.

The Mortality Behind the Numbers

The death toll hidden in incidence figures deserves scrutiny. In 2014, TB caused an estimated 1.5 million deaths worldwide. Of those, roughly 400,000 were formally attributed to AIDS deaths because they occurred in people living with HIV — a classification that is clinically accurate but has historically made TB less visible in mortality statistics and shifted how funding and political priority get allocated, BBC News noted at the time.

HIV-TB co-infection remains one of the disease's most difficult challenges. People with HIV have substantially higher risk of their latent TB becoming active disease, and patients with both infections need carefully coordinated medications that many under-resourced health systems cannot deliver consistently. The three-million annual diagnosis gap is not random — it concentrates precisely where co-infection is common and where drug-resistant TB strains are most prevalent.

What This Means for the Path Forward

England's shrinking caseload is genuine, but it operates within a global system. High-burden TB countries account for a substantial share of the UK's foreign-born TB cases, which means that when three million people globally go undiagnosed and untreated each year, it has direct implications for TB patterns in Britain. As long as that global pool of missed cases remains large, the pressure on cases arriving in low-incidence countries does not decrease.

WHO's End TB Strategy aims for a 90% reduction in TB deaths and an 80% reduction in incidence by 2030, using 2015 as the baseline. The 2022 data — 7.5 million cases identified from an estimated 10.6 million — indicates the required pace is not being met. COVID-19 severely disrupted TB services from 2020 to 2022, straining the diagnostic and treatment systems that had been gradually improving. Some recovery has occurred since, but WHO assessments describe progress as incomplete.

For TB control specialists and public health officials, the question becomes which problems are solvable within current systems and which require deeper structural change. England's continued focus on latent TB screening and community-based case-finding can continue to work. But the global shortfall in diagnostic capacity, the insufficient funding for new TB drugs relative to the disease burden, and the classification issues that have obscured TB deaths in HIV-affected regions — these remain unresolved at a larger scale. England's success is instructive. Replicating it globally is a far harder problem.